Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Journal for ImmunoTherapy of Cancer

Mai Yoshida¹  Hidehisa Saeki¹  Ryoko Takayama¹  Yoko Funasaka¹  Yuji Minegishi²  Teppei Sugano²  Susumu Takeuchi²  Asuka Nakanishi²  Rintaro Noro²  Kaoru Kubota²  Akihiko Gemma²  Toru Tanaka²  Ken Okamura²  Masahiro Seike² 

[1] Department of Dermatology, Nippon Medical School;Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School;

关键词: Lung adenocarcinoma;    Pembrolizumab;    Intralymphatic histiocytosis;   

DOI  :  10.1186/s40425-019-0534-z

来源: DOAJ

【 摘 要 】

Abstract Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induce various immune-related adverse events, involving the lung, liver, gastrointestinal, endocrine system, and skin. Intralymphatic histiocytosis (ILH) is a rare, chronic cutaneous disorder with a reactive inflammatory component, which often occurs in patients with rheumatoid arthritis. Case presentation We present a 67-year-old man with lung adenocarcinoma who developed ILH associated with pembrolizumab treatment. He was treated with palliative thoracic radiotherapy for superior vena cava syndrome. Subsequently, he received four cycles of pembrolizumab. Approximately 2.5 months after the initiation of pembrolizumab, he developed erythema on the trunk of his body. Based on findings of skin biopsies, he was diagnosed with pembrolizumab-induced ILH. Moreover, the upregulation of tumor necrosis factor-α was observed during pembrolizumab therapy. Conclusions This is the first report of ILH induced by pembrolizumab in a patient with lung adenocarcinoma.

【 授权许可】

Unknown